<div class="infobox infobox-company">
<div class="infobox-header">Neurolixis SAS</div>
<div class="infobox-row"><strong>Headquarters:</strong> Montpellier, France</div>
<div class="infobox-row"><strong>Founded:</strong> 2009</div>
<div class="infobox-row"><strong>Private:</strong> Venture-backed</div>
<div class="infobox-row"><strong>Status:</strong> Active</div>
<div class="infobox-row"><strong>Website:</strong> neurolixis.com</div>
</div>
<div class="infobox infobox-company">
<div class="infobox-header">Neurolixis SAS</div>
<div class="infobox-row"><strong>Headquarters:</strong> Montpellier, France</div>
<div class="infobox-row"><strong>Founded:</strong> 2009</div>
<div class="infobox-row"><strong>Private:</strong> Venture-backed</div>
<div class="infobox-row"><strong>Status:</strong> Active</div>
<div class="infobox-row"><strong>Website:</strong> neurolixis.com</div>
</div>
Neurolixis is a French biotechnology company developing novel therapeutics for [Parkinson's disease](/diseases/parkinsons-disease) and other central nervous system disorders. Founded in 2009 and headquartered in Montpellier, France, the company's focus is on selective serotonin receptor agonists and other small molecules targeting neuropsychiatric symptoms of neurodegenerative diseases["@neurolixis"].
The company addresses a significant unmet need in Parkinson's disease management: levodopa-induced dyskinesia (LID), a debilitating side effect that affects up to 50% of patients after 5-10 years of levodopa treatment. Neurolixis's approach targets the serotonin system, which plays a critical role in regulating dopamine release and motor control["@hta"].
Neurolixis was founded based on research from French academic institutions, particularly work on serotonin receptor pharmacology and its relationship to movement disorders. The company's scientific advisory board includes leading experts in Parkinson's disease and neuropharmacology from universities across Europe.
The company operates as a virtual biotech, leveraging partnerships for clinical development while maintaining focus on discovery and early-stage research. This model allows Neurolixis to minimize overhead while progressing multiple programs through the pipeline.
NLX-112 is Neurolixis's lead clinical candidate, a highly selective serotonin 5-HT1A receptor agonist being developed for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients[@nlx].
| Attribute | Details |
|-----------|---------|
| Mechanism | 5-HT1A full agonist |
| Indication | Levodopa-induced dyskinesia (PD-LID) |
| Route | Oral |
| Development Phase | Phase 2 |
| Status | Active clinical development |
Mechanism of Action:
NLX-112 works by activating 5-HT1A receptors in the basal ganglia, which helps normalize dopamine signaling and reduces the excessive movement that characterizes dyskinesia. Unlike current treatments that either reduce levodopa dose or block dopamine receptors (causing worsening of Parkinson's symptoms), NLX-112 is designed to reduce dyskinesia without compromising motor control[@serotonergic2020].
Clinical Development:
NLX-101 is a 5-HT1A agonist being developed for Rett Syndrome, a rare neurodevelopmental disorder characterized by severe cognitive and motor impairments[@nlxa].
| Attribute | Details |
|-----------|---------|
| Mechanism | 5-HT1A partial agonist |
| Indication | Rett Syndrome |
| Development Phase | Preclinical |
| Status | Active research |
NLX-204 is a 5-HT2A inverse agonist being developed for Parkinson's disease psychosis[@nlxb].
| Attribute | Details |
|-----------|---------|
| Mechanism | 5-HT2A inverse agonist |
| Indication | PD Psychosis |
| Development Phase | Preclinical |
| Status | Active research |
Neurolixis's platform centers on selective modulation of serotonin (5-HT) receptors, particularly:
Levodopa-induced dyskinesia represents a significant unmet medical need:
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Neurolixis | NLX-112 | 5-HT1A agonist | Phase 2 |
| Merck | -- | -- | Research |
| Pfizer | -- | -- | Research |
| Event | Year | Details |
|-------|------|---------|
| Seed Round | 2017 | Initial funding from European venture investors |
| Series A | 2020 | Financing to advance NLX-112 to Phase 2 |
NLX-112 Phase 1 Trial (2022): The first-in-human study demonstrated good safety and target engagement in healthy volunteers. The compound showed dose-proportional pharmacokinetics and achieved sufficient brain exposure. These results supported advancement to Phase 2 planning[@nlxc].